ClinicalTrials.gg
RecruitingNCT05902988Updated Nov 4, 2025

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

A Phase 1/2 interventional study of VLS-1488 in Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary and Squamous Non-small-cell Lung Cancer, sponsored by Volastra Therapeutics, Inc.. Recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-04.

Primary conditionnone(registry's first term: Triple Negative Breast Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Triple Negative Breast Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Volastra Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

Read the detailed description

This a first-in-human phase I/II study designed to assess the safety, tolerability and preliminary efficacy of VLS-1488 monotherapy and consists of two parts: Dose Escalation and Dose Expansion.

Dose Escalation will examine the safety and tolerability of VLS-1488 in different solid tumor types at various dose levels through a series of Dose Escalation and Backfill Cohorts to identify the Maximum Tolerated Dose (MTD) and to select dose levels for Dose Expansion. The criteria for dose (de-)escalation will be based on a Bayesian Optimal Interval (BOIN) design.

Dose Expansion will examine the safety, tolerability, Drug Drug Interaction (DDI) risk, Food Effect (FE) and preliminary efficacy of VLS-1488 in different tumor types and/or dose levels of interest through various expansion cohorts.

VLS-1488 will be given orally in 28-day cycles. Dosing will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or other stopping criteria are met.

02

Conditions studied

  • Advanced Solid Tumor
  • High Grade Serous Adenocarcinoma of Ovary
  • Squamous Non-small-cell Lung Cancer
  • Triple Negative Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
  • Uterine Serous Carcinoma
  • Endometrium Cancer
  • Chromosomal Instability

Keywords

  • KIF18A Inhibitor
  • HGSOC
  • TNBC
  • HNSCC
  • sqNSCLC
03

In context

Lead sponsor

Volastra Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • All Parts: Age ≥ 18 years, Performance Status ≤ 1, at least 1 site of evaluable by CT scan or MRI per 1.1, able to take oral medication without alteration
  • Dose Escalation: No available therapeutic options to provide benefits in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non -Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction, Bladder (transitional cell), Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), Ovarian Carcinosarcoma, CN-high Endometrial/Uterine
  • Dose Expansion: Must have been previously treated with several lines of standard of care treatment specified in the protocol in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), CN-high Endometrial/Uterine

Key Exclusion Criteria:

  • MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype
  • Previously received KIF18A inhibitor
  • Current or
  • Cardiac parameters: MI or stroke ≤ 1 year, unstable angina/PE/DVT/CABG ≤ 6 months, Class ≥ II, \< 50%
  • Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of , and clinical inhibitors of MDR1 (P-gp) and BCRP
  • Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug
  • Bowel obstruction or GI perforation within 6 months of planned first dose of study drug
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Dose Escalation: Dose Escalation Cohorts

    Subjects will be enrolled at various doses and/or schedules of VLS-1488. These Dose Escalation Cohorts will be utilized to identify the MTD and to select dose levels for Dose Expansion.

    Drug: VLS-1488

  • Experimental
    Dose Escalation: Backfill Cohorts

    Additional subjects may be enrolled at any dose level that does not meet de-escalation or elimination rules per the BOIN design. These Backfill Cohorts will be utilized to build additional data to support selection of doses and/or tumor types for further study in Dose Expansion.

    Drug: VLS-1488

  • Experimental
    Dose Expansion: Exploration Cohorts

    Subjects with a selected single tumor type will be randomized 1:1 into Exploration Cohorts at two or more dose levels of interest. A subset of subjects will have additional assessments to examine the potential for VLS-1488 to interact with other drugs and the effect of food on VLS-1488 absorption.

    Drug: VLS-1488

  • Experimental
    Dose Expansion: Development Cohorts

    Subjects with other tumor types will be enrolled at a single dose level of interest. These Development Cohorts will be utilized to examine the preliminary efficacy of VLS-1488 in various tumor types.

    Drug: VLS-1488

Interventions

  • DrugVLS-1488

    VLS-1488 tablets will be given orally.

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects

    Time frame: Up to 12 months

  2. Dose Escalation: Determination of the MTD of VLS-1488

    Time frame: Up to 12 months

  3. Dose Escalation: Frequency of Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

    Time frame: Up to 12 months

  4. Dose Escalation: Frequency of Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0

    Time frame: Up to 12 months

  5. Dose Escalation: Frequency of Treatment-Emergent AEs (TEAEs) graded per NCI-CTCAE version 5.0

    Time frame: Up to 12 months

  6. Dose Escalation: Frequency of Dose Interruptions and Permanent Treatment Discontinuations

    Time frame: Up to 12 months

  7. Dose Expansion: Frequency of Trigger Events (TEs)

    Time frame: Up to 18 months

  8. Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Up to 18 months

Secondary outcomes

  1. Dose Escalation: ORR as assessed by RECIST version 1.1

    Time frame: Up to 12 months

  2. Dose Expansion: Frequency of SAEs graded according to NCI-CTCAE version 5.0

    Time frame: Up to 18 months

  3. Dose Expansion: Frequency of Treatment-related AEs graded according to NCI-CTCAE version 5.0

    Time frame: Up to 18 months

  4. Dose Expansion: Frequency of TEAEs graded according to NCI-CTCAE version 5.0

    Time frame: Up to 18 months

  5. Dose Expansion: Frequency of Dose Interruptions and Permanent Treatment Discontinuations

    Time frame: Up to 18 months

  6. Dose Expansion: Area Under the Plasma Concentration-Time Curve (AUC) of Midazolam and its metabolite 1'-hydroxymidazolam

    Time frame: Up to 18 months

  7. Dose Expansion: Maximum Plasma Concentration (Cmax) of Midazolam and its metabolite 1'-hydroxymidazolam

    Time frame: Up to 18 months

  8. Dose Expansion: Evaluation of CA-125 response by Gynecologic Cancer InterGroup (GCIG) criteria (High Grade Serous Ovarian Cancer only)

    Time frame: Up to 18 months

  9. Dose Escalation & Dose Expansion: Duration of Response (DOR) as assessed by RECIST version 1.1

    Time frame: Up to 32 months

  10. Dose Escalation & Dose Expansion: Disease Control Rate (DCR) as assessed by RECIST version 1.1

    Time frame: Up to 32 months

  11. Dose Escalation & Dose Expansion: Progression Free Survival (PFS) as assessed by RECIST version 1.1

    Time frame: Up to 32 months

  12. Dose Escalation & Dose Expansion: Cmax of VLS-1488

    Time frame: Up to 32 months

  13. Dose Escalation & Dose Expansion: AUC of VLS-1488

    Time frame: Up to 32 months

  14. Dose Escalation & Dose Expansion: Trough Concentration (Ctrough) of VLS-1488

    Time frame: Up to 32 months

  15. Dose Escalation & Dose Expansion: Time to Maximum Plasma Concentration (Tmax) of VLS-1488

    Time frame: Up to 32 months

  16. Dose Escalation & Dose Expansion: Ratio of Total Cholesterol to 4β-hydroxycholesterol in plasma

    Time frame: Up to 32 months

  17. Dose Escalation & Dose Expansion: Increase in the number of Phospho-Histone 3 positive tumor cells

    Time frame: Up to 32 months

  18. Dose Escalation & Dose Expansion: Frequency of Micronucleated Reticulocytes in blood

    Time frame: Up to 32 months

  19. Dose Escalation & Dose Expansion: Increase in Micronuclei in Circulating Tumor Cells

    Time frame: Up to 32 months

07

Study locations

13 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Jun 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 15, 2023
StartActual
Oct 18, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05902988
Lead sponsor
Volastra Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Oct 18, 2023
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 4, 2025

Study contacts

Volastra Therapeutics, Inc.
Contact
clinicaltrials@volastratx.com
(646) 344-1248

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion